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Total hip arthroplasty (THA) is the most eﬀective treatment for advanced or end-stage hip osteoar-
thritis.  However,  venous thromboembolism (VTE) remains one of its unresolved complications.  We 
reviewed the records of 322 patients undergoing primary THA and investigated the eﬃcacy of antico-
agulant prophylaxis for VTE.  Our study cohort consisted of 60 patients who received no anticoagu-
lants,  100 patients who received a factor Xa inhibitor (fondaparinux),  100 patients who received low 
molecular weight heparin (enoxaparin),  and 62 patients who selectively received no anticoagulant 
prophylaxis due to perioperative bleeding,  weight,  and/or hemoglobin concentration.  Enhanced 
64-slice multidetector row computed tomography was performed postoperatively for 7 days in all 
cases.  The incidence of VTE in the four groups was 15ｵ,  9.0ｵ,  6.0ｵ,  and 6.4ｵ,  respectively.  The 
incidence of VTE was signiﬁcantly lower in the groups receiving anticoagulant prophylaxis and the 
group selectively receiving no anticoagulant prophylaxis than in the group receiving no anticoagulants.  
Complications of fondaparinux therapy included hepatic dysfunction in 4 cases (4.0ｵ),  minor bleeding 
in 2 cases (2.0ｵ),  persistent wound drainage in 3 cases (3.0ｵ),  and eruption in 1 case (1.0ｵ).  The 
complications of enoxaparin therapy were persistent wound drainage in 1 case (1.0ｵ) and progression 
of anemia in 1 case (1.0ｵ).  The incidence of VTE was low in patients who selectively received no 
anticoagulant prophylaxis,  so we conclude that anticoagulant prophylaxis should be used selectively in 
THA cases.
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enous thromboembolism (VTE) is a periopera-
tive complication of total hip arthroplasty 
(THA).  According to the Japanese guideline for the 
prevention of venous thromboembolism [1],  patients 
undergoing THA are at high risk for developing VTE 
and are recommended to receive preventive therapy.  
The recommended methods of preventing VTE are the 
use of compression stockings,  intermittent pneumatic 
compression (IPC),  anticoagulants,  and other thera-
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pies.  The usefulness of anticoagulants for the preven-
tion of VTE has been described by the American 
Academy of Orthopedic Surgeons (AAOS) and the 
American College of Chest Physicians (ACCP) [2],  
as well as in recent studies [3-5].  However,  compli-
cations such as bleeding can be serious [6].  In Japan,  
secondary osteoarthritis of the hip is the leading reason 
for THA [7].  The operation for secondary osteoar-
thritis is more complicated than that for primary 
osteoarthritis of the hip,  so the operative time and 
levels of perioperative bleeding are diﬀerent in each 
case.  
　 Duplex ultrasonography (US) is commonly used for 
VTE screening [8],  but it cannot detect pulmonary 
thromboembolism (PE).  In our institute,  enhanced 
computed tomography (e-CT) was performed one week 
after surgery to screen for deep vein thromboembo-
lism (DVT) and PE simultaneously.  We hypothesized 
that anticoagulant prophylaxis should be used selec-
tively in THA cases,  and that enhanced CT would be 
a useful screening method for asymptomatic VTE.
Materials and Methods
　 Patients undergoing primary THA between May 
2006 and December 2010 were divided into 4 groups 
after written informed consent was obtained.  Based on 
the method of VTE prophylaxis,  group A (n＝60) 
received no anticoagulant prophylaxis between May 
2006 and July 2007,  group B (n＝100) received a 
factor Xa inhibitor (fondaparinux; FPX) between July 
2007 and December 2008,  group C (n＝100) received 
low molecular weight heparin (enoxaparin;  LMWH) 
between January 2009 and December 2010,  and group 
D (n＝62) patients selectively received no anticoagu-
lant prophylaxis―i.e.,  neither LMWH nor FPX―
between July 2007 and December 2010 (Table 1).  
The dose of FPX was 2.5mg in patients with a creati-
nine clearance of＞30 ml/min,  and 1.5mg in patients 
with a creatinine clearance of 20-30ml/min.  The 
dose of LMWH was 4,000IU/day in patients with a 
creatinine clearance of＞50ml/min,  and 2,000IU/day 
in patients with a creatinine clearance of 30-50ml/
min.  Patients who could not receive anticoagulants 
due to a volume of postoperative blood loss of＞600ml 
on postoperative days 0 to 2,  weight＜50kg,  and/or 
a hemoglobin level of＜9g/dl the day after surgery 
belonged to group D.  We used a navigation system to 
position the acetabular cup prosthesis in all cases of 
cemented THA (n＝73) and cementless THA (n＝249).  
The transtrochanteric,  anterolateral,  or posterior 
approach was used with the patient placed in the supine 
or lateral decubitus position.  All patients received 
1,500ml of Ringerʼs solution or hydroxyethyl starch 
daily for 3 days postoperatively.  IPC was applied for 
2 days postoperatively,  with the application limited to 
nighttime hours for 1 week postoperatively,  after 
ambulation was permitted.  In groups B and C,  pro-
phylaxis began on postoperative day 2 and was contin-
ued for 10 days.  Those receiving anticoagulants such 
as warfarin and heparin preoperatively,  those not able 
to undergo examination for VTE by e-CT because of 
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Table 1　 Patient demographics,  body mass index,  and operative time for each group
Group
A
No
anticoagulants
B
Fondaparinux
C
LMWH
D
No anticoagulants
selectively
Hips 60 100 100 62
Disease
(OA, RA, ION)
53 : 4 : 3 83 : 8 : 9 88 : 3 : 9 41 : 12 : 9
Gender (F/M) 53 : 4 78 : 22 91 : 9 59 : 3
Age 66 (41～84) 58 (35～82) 61 (40～86) 62 (25～80)
BMI 24 (14～34) 23 (16～40) 24 (17～45) 22 (14～30)
Operative time (min) 115 (60～220) 103 (59～185) 101 (60～180) 113 (60～180)
LMWH,  low molecular weight heparin; OA,  osteoarthritis; RA,  rheumatoid arthritis; ION,  idiopathic osteonecrosis; F/M,  female/male;  
BMI,  body mass index.  The number of hips and gender distribution are diﬀerent in group A,  because group A included 3 bilateral cases.
allergy and renal dysfunction,  and those not able to 
receive anticoagulants due to renal dysfunction were 
excluded from this study.
　 Enhanced 64-slice multidetector row computed 
tomography (MDCT) was performed in all 322 cases 
at 7 days postoperatively,  and VTE was diagnosed by 
our in-hospital radiologists.  Complications of antico-
agulant prophylaxis including hepatic dysfunction,  
bleeding,  persistent wound drainage,  eruptions,  and 
progression of anemia were assessed.  Hepatic dys-
function was deﬁned as an increase in aspartate amin-
otransferase (AST) or alanine aminotransferase (ALT) 
levels by two or more times the upper limit of normal 
(AST 70IU/l,  ALT 84IU/l).  Bleeding was deﬁned as 
marked swelling and internal hemorrhaging at the 
wound site.  Persistent wound drainage was deﬁned as 
wound drainage that continued more than 2 weeks 
postoperatively.  Eruptions that developed after 
administration of anticoagulants were diagnosed by 
dermatologists.  Progression of anemia was deﬁned as 
a decrease in the hemoglobin level of＞2g/dl at 3 days 
postoperatively; treatment with anticoagulant prophy-
laxis was stopped when this diagnosis was made.  
Plasma D-dimer levels were also assessed with a 
random access,  high-volume coagulation analyzer 
(CS-5100; Sysmex Corporation,  Kobe,  Japan).  The 
normal range was lower than 0.9µg/ml.  We also 
compared the hemoglobin values and D-dimer levels in 
each group on postoperative days 1,  3,  5,  and 7.
　 Statistical analyses were carried out using SPSS 
version 19.0 (IBM,  New York,  NY,  USA).  The chi-
squared test was used to compare the incidence of 
VTE,  and the unpaired Studentʼs t-test was employed 
to compare diﬀerences in hemoglobin and D-dimer 
levels between groups.  A p-value of＜0.05 was con-
sidered statistically signiﬁcant.  
　 This study was conducted in accordance with the 
Helsinki Declaration.  Ethical approval was obtained 
from the institutional review board of Okayama 
University (approval number: 982).
Results
　 A total of 9 cases of venous thromboembolism 
(VTE; 15ｵ),  including 4 cases of deep vein throm-
boembolism (DVT; 6.7ｵ),  3 cases of pulmonary 
embolism (PE; 5.0ｵ),  and 2 cases of both DVT and 
PE (3.0ｵ),  were detected in group A.  Nine cases of 
VTE (9.0ｵ),  including 6 cases of DVT (6.0ｵ),  1 case 
of PE (1.0ｵ),  and 2 cases (2.0ｵ) of both DVT and 
PE,  were detected in group B.  Six cases of VTE 
(6.0ｵ),  including 4 cases (4.0ｵ) of DVT and 2 cases 
(2.0ｵ) of PE,  were detected in group C.  Four cases 
(6.4ｵ) of VTE,  including 3 cases (4.8ｵ) of DVT and 
1 case (1.6ｵ) of both DVT and PE,  were detected in 
group D (Fig. 1).  Statistically signiﬁcant diﬀerences 
were not found between groups.  There were no cases 
of symptomatic VTE.  After thrombolytic therapy,  the 
thrombi disappeared or became smaller on e-CT re-
examination.
　 Complications in group B (10 cases,  10.0ｵ) included 
hepatic dysfunction in 4 cases (4.0ｵ),  minor bleeding 
in 2 cases (2.0ｵ),  persistent wound drainage in 3 cases 
(3.0ｵ),  and eruption in 1 case (1.0ｵ).  Complications 
in group C (2 cases,  2ｵ) included persistent wound 
drainage in 1 case (1.0ｵ) and progression of anemia in 
1 case (1.0ｵ).  The prevalence of hepatic dysfunction 
in group B was signiﬁcantly higher than that in group 
C.  There were no cases of severe bleeding requiring 
blood transfusion.
　 Postoperative hemoglobin and D-dimer levels were 
compared.  The mean hemoglobin level was signiﬁcantly 
lower in group D compared with the other groups on 
postoperative day 1 (Fig. 2).  The mean D-dimer level 
reached its nadir on postoperative day 3 in each group,  
then increased gradually,  and was signiﬁcantly lower 
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Fig. 1　 The bar graph shows the VTE incidence in group A 
(receiving no anticoagulants),  group B (receiving FDX),  group C 
(receiving enoxaparin),  and group D (selectively receiving no anti-
coagulants).  The incidences of DVT,  PE,  and both PE and DVT 
are indicated by the white bar,  striped bar,  and dotted bar,  respec-
tively.
in groups B and C than in groups A and D on postop-
erative day 7 (Fig. 3).  In patients with VTE on post-
operative day 7,  the mean D-dimer level was＞10µg/ml 
in groups A and D and＜10µg/ml in groups B and C 
(Fig. 4).  If we set the cutoﬀ value for the D-dimer level 
as 10µg/ml,  the sensitivity in groups A,  B,  C,  and 
D was 0.778,  0.556,  0.500,  and 0.750,  respectively.  
The speciﬁcity in groups A,  B,  C,  and D was 0.412,  
0.637,  0.628,  and 0.414,  respectively (Table 2).
　 Case 1. This patient was a 58-year-old Japanese 
woman who underwent a closed reduction for develop-
mental dislocation of the hip.  Her height,  weight,  and 
body mass index (BMI) were 155cm,  55kg,  and 23,  
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Fig. 2　 The average hemoglobin level in each group.  Values are 
shown for postoperative days 1,  3,  5 and 7,  plotted for group A 
(receiving no anticoagulants),  group B (receiving FDX),  group C 
(receiving enoxaparin),  and group D (selectively receiving no antico-
agulants),  and indicated by rhombuses,  squares,  triangles,  and Xs,  
respectively.  Values under the group are the cases in each group.
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Fig. 3　 The average D-dimer level in each group.  Values are 
shown for postoperative days 1,  3,  5 and 7.  Values under the group 
are the cases in each group.
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Fig. 4　 The average D-dimer level in VTE patients of each group.  
D-dimer levels are shown on postoperative days 1,  3,  5 and 7.  
Values under the group are the cases in each group.
(A) (B)
Fig. 5　 The anteroposterior (AP) view of the hip joints in case 1.  (A) Preoperative and (B) postoperative radiographs.
respectively.  Cemented THA was performed.  The 
operative time,  intraoperative blood loss (Fig. 5A, B),  
and perioperative blood loss were 175min,  500ml,  
and＞600ml,  respectively,  so she did not require 
anticoagulant prophylaxis and could ambulate 2 days 
postoperatively.  One week after surgery,  her 
D-dimer level was 22.3µg/ml,  but no VTE was 
detectable on e-CT (Fig. 6).
　 Case 2. This patient was a 59-year-old American 
woman who lived in Japan.  She had systemic lupus 
erythematosus and osteonecrosis of the right femoral 
head.  Her height,  weight,  and BMI were 168cm,  
88kg,  and 31,  respectively.  Ten years after the onset 
of right coxalgia,  cementless THA was performed 
(Fig. 7A, B).  The operative time and intraoperative 
blood loss were 90min and 100ml,  and no blood 
transfusion,  including auto-blood transfusion,  was 
performed.  She could ambulate with a walker 2 days 
after surgery,  after which prophylactic LMWH was 
started.  Seven days postoperatively,  she had a hemo-
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Fig. 6　 Enhanced CT scan of the lung and the lower leg in case 1.  (A) PE was not detected in the entire lung.  (B) DVT was not 
detected in the lower legs,  neither.
Table 2　 Diagnosis of VTE using a D-dimer level cutoﬀ of 10µg/ml on postoperative day 7 in each group
Group
A
No anticoagulants
B
Fondaparinux
C
LMWH
D
No anticoagulants
 selectively
VTE(+)
10≧ 7 5 3 3
10＜ 2 4 3 1
sensitivity 0.778 0.556 0.500 0.750
spesiﬁcity 0.412 0.637 0.628 0.414
(A) (B)
Fig. 7　 Anteroposterior (AP) view of the hip joints in case 2.  (A) Preoperative and (B) postoperative radiographs.
globin level of 6g/dl and did not complain of any 
symptoms.  On e-CT,  a PE alone was detected (Fig.  
8).  Thrombolytic treatment with heparin was started.  
Reevaluation by e-CT after treatment found no 
thrombi and no VTE recurrence.
Discussion
　 In the United States and Europe,  VTE has been 
recognized as a serious complication of orthopedic 
surgery since the 1960s.  Screening for VTE and VTE 
prevention have been previously discussed [9].  Hume 
et al.  [10] evaluated the incidence of lower leg DVT 
in 140 THA cases by impedance phlethysmography 
and 125I-ﬁbrinogen leg scanning; they found that one-
quarter (35 patients) had VTE and mentioned the 
necessity of monitoring and routine prophylaxis.  
Harris et al.  [11] screened for VTE by cuﬀ-imped-
ance phlebography and 125I-ﬁbrinogen scanning.  They 
found that the accuracy of DVT detection was 80ｵ by 
cuﬀ-impedance phlebography and 78ｵ by 125I ﬁbrino-
gen scanning; the eﬀectiveness of cuﬀ-impedance 
phlebography for detecting proximal thrombi was 
noted.  Moskovitz et al.  [12] administered low dose 
heparin for prevention of VTE in 67 patients undergo-
ing THA.  In their randomized double-blinded study,  
they used 125I-ﬁbrinogen and venography to ﬁnd VTE 
and radionuclide lung scanning to detect the onset of 
PE.  VTE incidence was signiﬁcantly lower in the 
prophylactic heparin group (23ｵ) than in the placebo 
group (59ｵ).  However,  the prophylactic heparin 
group required a signiﬁcantly larger volume of trans-
fused blood than the placebo group.
　 Two decades after these reports,  VTE began to be 
recognized as a major complication of hip and knee 
arthroplasty in Japan.  Using venograms to screen for 
VTE in 164 THA cases,  Fujita et al.  [13] found 
DVT in 22.6ｵ and proximal DVT in 9.8ｵ.  At our 
institute,  Shiota et al.  [14] used bilateral venography 
to screen 54 patients with THA and found DVT in 22 
of these cases (40.1ｵ).  As a result of their report,  
the use of IPC and early ambulation are now recom-
mended in Japan.  Recently,  anticoagulant prophylaxis 
was also initiated for cases of TKA,  THA,  and hip 
fracture in Japan.
　 In a double-blinded,  randomized study of the eﬃcacy 
of fondaparinux (FDX; placebo,  0.75,  1.5,  2.5,  and 
3.0mg) in 74,  62,  65,  68,  and 70 patients,  respec-
tively,  Fuji et al.  [15] reported that the incidence of 
VTE (detected by ascending venography 11-17 days 
postoperatively) was 33.8ｵ,  24.2ｵ,  4.6ｵ,  7.4ｵ,  
and 9.5ｵ,  respectively.  Although there was a dose-
response eﬀect,  there were no statistically signiﬁcant 
inter-group diﬀerences in major events; it was con-
cluded that FDX has a favorable beneﬁt-to-risk proﬁle 
in patients with VTE.  Yamaguchi et al.  [3] adminis-
tered 2.5mg of FDX for 2 postoperative weeks to 71 
patients undergoing THA and screened for VTE by 
ultrasonography on postoperative days 1,  4,  and 14.  
DVT was detected in 27ｵ of patients on postopera-
tive day 4,  but in only 11.9ｵ of patients on postop-
erative day 14. Yukizawa et al.  [16] investigated 170 
THA cases,  including 67 cases treated with IPC only 
and 103 cases treated with IPC and FDX.  The inci-
dence of VTE detected by MDCT and duplex ultra-
sonography was 25ｵ in patients treated with IPC 
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(A) (B)
Fig. 8　 Enhanced CT scan of the lung and the lower leg in case 2. (A) The axial image showed thrombus (arrow) in the A10 
artery of the right lung. (B) The axial image revealed no DVT in the lower legs.
only and 8ｵ in patients treated with IPC and FDX.  
These recent reports indicate that anticoagulant pro-
phylaxis is eﬀective for the prevention of VTE in THA 
cases.
　 In our study,  VTE was detected by 64-slice MDCT 
7 days postoperatively,  and the VTE incidence was 
15ｵ in group A (no anticoagulants),  9ｵ in group B 
(FDX),  and 6ｵ in group C (LMWH).  The diﬀerence 
between groups was not statistically signiﬁcant.  
However,  previous reports indicated a decrease in 
VTE incidence as a result of prophylaxis [3,  15,  
17].  VTE incidence was lower in our report than in 
Shiotaʼs report [14]; prophylaxis for VTE consisted 
of only IPC without anticoagulants and patients ambu-
lated 1 week postoperatively.  For this reason,  we 
consider that anticoagulant prophylaxis and an early 
ambulation protocol will decrease VTE incidence.
　 Duplex ultrasonography is a common VTE screen-
ing method because of its low cost and convenience.  
On the other hand,  e-CT has some disadvantages such 
as exposure to radiation,  allergy to iodinated contrast 
media,  and high cost.  However,  the e-CT scan covers 
the entire body and can detect sites of PE and DVT 
simultaneously.  In the current study,  1.9ｵ,  5.3ｵ,  
1.6ｵ,  and 8.7ｵ of all 322 patients had PE,  DVT,  
PE＋DVT,  and VTE 1 week postoperatively,  
respectively; PE completely resolved on reexamina-
tion.  Thus,  we consider that the PEs detected by 
e-CT were not fat emboli,  so e-CT is needed for 
screening of asymptomatic VTE.
　 When using the D-dimer level as a screening test 
for VTE 1 week postoperatively,  Shiota et al.  [14] 
set the cutoﬀ value at 10µg/ml.  In our current study,  
the D-dimer level at 1 week postoperatively was sig-
niﬁcantly higher in groups A and D (＞10µg/ml) than 
in groups B and C,  so we set the cutoﬀ value at 
10µg/ml to screen for VTE at 1 week postoperatively.  
Yukizawa et al.  [16] deﬁned the cutoﬀ value as the 
increase in plasma soluble ﬁbrin and plasminogen-
activator inhibitor-1 levels from the preoperative to 
1-day postoperative period,  and found that the sensi-
tivity and speciﬁcity were 100ｵ and 67ｵ,  respec-
tively,  in the IPC group and 88ｵ and 97ｵ,  respec-
tively,  in the FDX group.  They also mentioned that 
it was ineﬃcient to investigate the D-dimer level as a 
marker for VTE 1 week postoperatively,  because the 
plasma D-dimer level increases following thrombus 
cleavage and activated plasmin is already formed.  In 
the current study,  the average plasma D-dimer level 
in the groups with anticoagulant prophylaxis was lower 
than that in those receiving no anticoagulant prophy-
laxis (Fig.  3 and 4).  It is useful to set a D-dimer cutoﬀ 
value of 10µg/ml in the cases receiving no anticoagu-
lant prophylaxis,  but this does not apply in the antico-
agulant prophylaxis cases (Table 2).  Shimoyama et al.  
[17] reported that a preoperative D-dimer level of 
0.85µg/ml is a useful screening tool for VTE.  
Although they concluded that the evaluation of VTE 
risk before surgery is useful,  their study included a 
fairly small number of cases.  In the current study,  the 
preoperative D-dimer level was not determined for all 
cases,  and thus further prospective research is needed.  
　 Bleeding is an inevitable complication of anticoagu-
lant prophylaxis,  as previously reported [6,  12].  
Although the ACCP recommends the use of enox-
aparin sodium for VTE prophylaxis,  Burnett et al.  
[6] reported that major complications such as bleeding 
occurred 3 times more often in patients receiving 
enoxaparin sodium prophylaxis than in those treated 
with prophylactic warfarin.  In this study,  the inci-
dence of VTE was low in both the FDX and LMWH 
groups,  but without a signiﬁcant diﬀerence between 
the 2 groups.  The complication rate was higher in the 
FDX group.  VTE incidence was as low in the group 
selectively receiving no anticoagulant prophylaxis,  as 
in the groups receiving anticoagulant prophylaxis.  
VTE was not symptomatic in this series,  so we con-
sider that it is suﬃcient to use anticoagulants selec-
tively for VTE prophylaxis.  Sugano et al.  [18] 
reviewed 3016 patients undergoing elective hip sur-
gery.  Patients received intraoperative IPC,  early 
ambulation,  postoperative compression stockings,  and 
prophylactic IPC.  Although one patient with PE 
(0.003ｵ) and 4 patients with DVT (0.013ｵ) were 
symptomatic,  no case of PE was fatal.  In our study,  
all cases of VTE were detected by e-CT.  In Suganoʼs 
study,  no deaths had occurred within 6 months of 
treatment,  even in symptomatic cases.  They concluded 
that mechanical thromboprophylaxis without antico-
agulant prophylaxis was eﬀective enough.  Although we 
agree with their opinion,  not all their patients were 
screened.  We consider that the incidence of asymp-
tomatic VTE in THA cases is higher than previously 
reported and the risk of death in patients with asymp-
tomatic PE remains high.  
　 Our study was limited in that it had a retrospec-
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tive design and was not a randomized controlled trial.  
In addition,  there was a signiﬁcant bias in gender and 
the cause of THA between the 4 groups.  Finally,  we 
did not continue to screen for VTE after discharge.  
In the future,  a randomized controlled trial with a 
large number of patients,  as well as more detailed 
pre- and postoperative assessments,  will be needed.  
　 In conclusion,  we investigated the postoperative 
VTE incidence in THA cases for which anticoagulant 
prophylaxis was applied selectively based on e-CT.  
The results indicated that THA cases with periopera-
tive blood loss＞600ml and a hemoglobin level＜9.0g/
dl may not need anticoagulant prophylaxis to avoid the 
complication of bleeding.
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